Effect of Prior Therapy on the Efficacy and Safety of Oral Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Study

被引：1

作者：

Cavallo, Federica ^{[1
]}

Follows, George A. ^{[2
]}

Goy, Andre ^{[3
]}

Vermaat, Joost ^{[4
]}

Casasnovas, Rene-Olivier ^{[5
]}

Lavee, Orly ^{[6
]}

Maerevoet, Marie ^{[7
]}

Zijlstra, Josee M. ^{[8
]}

Bakhshi, Sameer ^{[9
]}

Bouabdallah, Reda

Choquet, Sylvain ^{[10
,11
]}

Gurion, Ronit ^{[12
]}

Hill, Brian T. ^{[13
]}

Jaeger, Ulrich ^{[14
]}

Sancho, Juan-Manuel ^{[15
]}

Schuster, Michael W. ^{[16
]}

Thieblemont, Catherine ^{[17
,18
]}

De la Cruz, Fatima ^{[19
]}

Egyed, Miklos ^{[20
]}

Mishra, Sourav ^{[21
]}

Offner, Fritz ^{[22
]}

Vassilakopoulos, Theodoros P. ^{[23
]}

Warzocha, Krzysztof ^{[24
]}

McCarthy, Daniel ^{[25
]}

Ma, Xiwen ^{[25
]}

Corona, Kelly ^{[25
]}

Saint-Martin, Jean-Richard ^{[25
]}

Joshi, Anita ^{[25
]}

Shah, Jatin ^{[25
]}

Van den Neste, Eric ^{[26
]}

Canales, Miguel A. ^{[27
]}

Kalakonda, Nagesh ^{[28
]}

机构：

[1] Univ Torino, Div Hematol, AOU Citta Salute & Sci, Turin, Italy

[2] Cambridge Univ Hosp NHS Fdn Trust, UK CLL Forum, Haematol, Cambridge, England

[3] Hackensack Univ Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA

[4] Leiden Univ Med Ctr, Dept Hematol, Leiden, Netherlands

[5] Univ Dijon, Dept Hematol, CHU Hop Francois Mitterrand, Dijon, France

[6] St Vincents Hosp, Darlinghurst, NSW, Australia

[7] ULB, Inst Jules Bordet, Dpt Hematol, Brussels, Belgium

[8] Vrije Univ Amsterdam, Canc Ctr Amsterdam, Dept Hematol, Amsterdam UMC, Amsterdam, Netherlands

[9] All India Inst Med Sci, Dr BRA Inst Rotary Canc Hosp, New Delhi, India

[10] Inst Paoli Calmettes, Dept Hematol, Marseille, France

[11] Hosp Pitie Salpetriere, Paris, France

[12] Rabin Med Ctr, Inst Hematol, Davidoff Canc Ctr, Petah Tiqwa, Israel

[13] Cleveland Clin, Cleveland, OH 44106 USA

[14] Med Univ Vienna, Vienna, Austria

[15] Hosp Badalona Germans Trias & Pujol, Barcelona, Spain

[16] SUNY Stony Brook, Hosp Canc Ctr, Stony Brook, NY USA

[17] Hop St Louis, AP HP, Hemato Oncol, Paris, France

[18] Diderot Univ, Sorbonne Paris Cite, Paris, France

[19] Hosp Univ Virgen del Rocio, Seville, Spain

[20] Mor Kaposi Teaching Hosp, Kaposvar, Hungary

[21] Inst Med Sci & SUM Hosp, Bhubaneswar, Odisha, India

[22] Univ Ziekenhuis Gent, Ghent, Belgium

[23] Natl & Kapodistrian Univ Athens, Laikon Gen Hosp, Athens, Greece

[24] Inst Haematol & Transfus Med, Clin Haematol, Warsaw, Poland

[25] Karyopharm Therapeut, Newton, MA USA

[26] Clin Univ St Luc, Brussels, Belgium

[27] Hosp Univ La Paz, Madrid, Spain

[28] Univ Liverpool, Liverpool, Merseyside, England

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-122900

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

5333

引用

页数：6

共 50 条

[1] Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study
Schuster, Michael
Zijlstra, Josee
Casasnovas, Rene-Olivier
Vermaat, Joost S. P.
Kalakonda, Nagesh
Goy, Andre
Choquet, Sylvain
Van Den Neste, Eric
Hill, Brian
Thieblemont, Catherine
Cavallo, Federica
De la Cruz, Fatima
Kuruvilla, John
Hamad, Nada
Jaeger, Ulrich
Caimi, Paolo
Gurion, Ronit
Warzocha, Krzysztof
Bakhshi, Sameer
Sancho, Juan-Manuel
Follows, George
Egyed, Miklos
Offner, Fritz
Vassilakopoulos, Theodoros
Samal, Priyanka
Ku, Matthew
Ma, Xiwen
Corona, Kelly
Chamoun, Kamal
Shah, Jatin
Shacham, Sharon
Kauffman, Michael G.
Canales, Miguel
Maerevoet, Marie
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (07): : 483 - 494
[2] Effect of Age on the Efficacy and Safety of Single Agent Oral Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Pivotal Study
Schuster, Michael W.
Canales, Miguel A.
Westin, Jason
Zijlstra, Josee M.
Follows, George A.
Karmali, Reem
Kalakonda, Nagesh
Goy, Andre H.
Casasnovas, Rene-Olivier
Vermaat, Joost
Van den Neste, Eric
Choquet, Sylvain
Thieblemont, Catherine
Cavallo, Federica
De La Cruz, Maria de Fatima
Hill, Brian T.
Tilly, Herve
Kassam, Shireen
Bouabdallah, Reda
Jaeger, Ulrich
Gurion, Ronit
Caimi, Paolo
Martin, Peter
Davies, Andrew
Smith, Sonali M.
Collins, Graham P.
Offner, Fritz C.
Salles, Gilles
Ma, Xiwen
Corona, Kelly
Saint-Martin, Jean-Richard
Joshi, Anita A.
Chamoun, Kamal
Wang, Hongwei
Shah, Jatin J.
Shacham, Sharon
Kauffman, Michael G.
Maerevoet, Marie
BLOOD, 2020, 136
[3] Selinexor Efficacy and Safety Are Independent of Renal Function in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis from the Pivotal Phase 2b Sadal Study
Schuster, Michael W.
Canales, Miguel A.
Westin, Jason
Zijlstra, Josee M.
Follows, George A.
Karmali, Reem
Kalakonda, Nagesh
Goy, Andre H.
Casasnovas, Rene-Olivier
Vermaat, Joost
Van den Neste, Eric
Choquet, Sylvain
Thieblemont, Catherine
Cavallo, Federica
De La Cruz, Maria de Fatima
Hill, Brian T.
Tilly, Herve
Kassam, Shireen
Bouabdallah, Reda
Jaeger, Ulrich
Gurion, Ronit
Caimi, Paolo
Martin, Peter
Davies, Andrew
Smith, Sonali M.
Collins, Graham P.
Offner, Fritz C.
Salles, Gilles
Ma, Xiwen
Corona, Kelly
Saint-Martin, Jean-Richard
Joshi, Anita A.
Chamoun, Kamal
Wang, Hongwei
Shah, Jatin J.
Shacham, Sharon
Kauffman, Michael G.
Maerevoet, Marie
BLOOD, 2020, 136
[4] A Phase 2b Study of Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Kalakonda, Nagesh
Cavallo, Federica
Follows, George
Goy, Andre
Vermaat, Joost S. P.
Casasnovas, Olivier
Lavee, Orly
Maerevoet, Marie
Zijlstra, Josee
Bakhshi, Sameer
Bouabdallah, Reda
Choquet, Sylvain
Gurion, Ronit
Hill, Brian
Jaeger, Ulrich
Sancho, Juan-Manuel
Schuster, Michael
Thieblemont, Catherine
De la Cruz, Fatima
Egyed, Miklos
Mishra, Sourav
Offner, Fritz
Vassilakopoulos, Theodoros
Warzocha, Krzysztof
McCarthy, Daniel
Ma, Xiwen
Corona, Kelly
Saint-Martin, Jean-Richard
Joshi, Anita
Shah, Jatin
Van den Neste, Eric
Canales, Miguel
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S248 - S249
[5] Acalabrutinib monotherapy in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Dyer, Martin J. S.
De Vos, Sven
Ruan, Jia
Flowers, Christopher
Maddocks, Kami J.
Rule, Simon
Hamdy, Ahmed M.
Izumi, Raquel
Slatter, J. Greg
Cheung, Jean
Frigualt, Melanie M.
Wei, Helen
Mourya, Sanchita
Hunder, Naomi N. H.
Fowler, Nathan Hale
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[6] Efficacy and Safety of Ibrutinib as Monotherapy or Combination Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL): A Systematic Review and Meta-analysis
Li, Yin
Li, Chunfan
Lv, Kebing
Wang, Shixuan
Li, Fei
AMERICAN JOURNAL OF THERAPEUTICS, 2025, 32 (01) : e5 - e16
[7] Total Cost of Care in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Gatwood, Justin
Masaquel, Anthony
Ross, Ryan
Sheinson, Danny
Hossain, Farah
Li, Jia
James, Cameron
Fox, David
BLOOD, 2022, 140 : 7906 - 7907
[8] The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study
Zijlstra, Josee M.
Follows, George
Casasnovas, Rene-Olivier
Vermaat, Joost S. P.
Kalakonda, Nagesh
Choquet, Sylvain
Hill, Brian
Thieblemont, Catherine
Cavallo, Federica
Cruz, Fatima De la
Kuruvilla, John
Hamad, Nada
Jaeger, Ulrich
Caimi, Paolo
Gurion, Ronit
Warzocha, Krzysztof
Bakhshi, Sameer
Sancho, Juan-Manuel
Schuster, Michael
Egyed, Miklos
Offner, Fritz
Vassilakopoulos, Theodoros P.
Samal, Priyanka
Ku, Matthew
Xu, Jenny
Corona, Kelly
Chamoun, Kamal
Shah, Jatin
Canales, Miguel
Maerevoet, Marie
CANCERS, 2022, 14 (03)
[9] SADAL Study: Selinexor, the oral solution without chemotherapy for Diffuse Large B-Cell Lymphoma?
Cailly, Laura
Guidez, Stephanie
HEMATOLOGIE, 2020, 26 (05): : 229 - 230
[10] Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Patients: A Retrospective Analysis of Eligibility Criteria for CAR-T Cell Therapy
Di Rocco, Alice
Di Rocco, Arianna
Farcomeni, Alessio
Petrucci, Luigi
De Luca, Giulia
Mazzon, Federico
Martelli, Maurizio
Foa, Robin
BLOOD, 2019, 134

← 1 2 3 4 5 →